Blackstone Gives Teva $400 Million to Develop Inflammatory Bowel Disease Treatment
By Elias Schisgall
Blackstone's life sciences group will pay Teva Pharmaceuticals $400 million over four years to support the development of duvakitug, Teva's treatment for inflammatory bowel disease.
If duvakitug is approved by the Food and Drug Administration, Teva will pay Blackstone a milestone payment. Blackstone is also eligible for commercial milestones and low single-digit royalties on global sales of duvakitug, the companies said Tuesday.
Teva's executive vice president for business development, Evan Lippman, said the agreement with Blackstone reflects the company's Pivot to Growth strategy.
"By pursuing disciplined, capital-efficient partnerships, we are accelerating pipeline advancement while maintaining financial strength,: Lippman said. "This is the model we will continue using to build a more innovative, resilient, and growth-oriented Teva."
Teva agreed in 2023 to jointly develop and commercialize the drug with Sanofi. The companies are currently running phase 3 studies for duvakitug to treat ulcerative colitis and Crohn's disease.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
March 03, 2026 17:35 ET (22:35 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States